Treatment of a patient with severe sarcoid lymphadenopathy using TNF- a -inhibitor (infliximab);Behandling af svær sarkoidose med tumornekrosefaktor alpha-hæmmer (infliximab)

Ugeskrift for Laeger

Volumn 168, Issue 5, 2006, Pages 484-485

  Milman, Nils ^a   Sørensen, Tina Brandt ^b  

^a Rigshospitalet   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB; METHOTREXATE; PREDNISOLONE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DRUG EFFECT; DRUG TOLERANCE; HUMAN; LYMPHADENOPATHY; MALE; SARCOIDOSIS; TREATMENT OUTCOME; LYMPHATIC SYSTEM DISEASE;

ADULT; ANTIBODIES, MONOCLONAL; HUMANS; LYMPHATIC DISEASES; MALE; SARCOIDOSIS; TREATMENT OUTCOME;

EID: 33644843722     PISSN: 00415782     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. The Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis (WASOG). Statement on sarcoidosis. Am J Respir Crit Care Med 1999;160:736-55.
2. Byg K-E, Milman N, Hansen S. Sarcoidosis in Denmark 1980-1994. Sarcoidosis Vasc Diffuse Lung Dis 2003;20:46-52.
3. Moller DR. Treatment of sarcoidosis - from a basic science point of view. J Intern Med 2003;253:31-40.
4. Ziegenhagen MW, Rothe ME, Zissel G et al. Exaggerated TNFα release of alveolar macrophages in corticosteroid resistant sarcoidosis. Sarc Vasc Diffuse Lung Dis 2002;19:185-90.
5. Doty JD, Mazur JE, Judson MA. Treatment of sarcoidosis with infliximab. Chest 2005;127:1064-71.